• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Halozyme Therapeutic (NQ: HALO )

    57.21 +6.64 (+13.13%)
    Streaming Delayed Price Updated: 2:59 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Halozyme Therapeutic

    < Previous 1 2 3 4 5 6 7 8 Next >
    Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
    Via Benzinga
    Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
    On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
    Via Investor's Business Daily
    Beam Therapeutics Stock Earns RS Rating Jump To 85
    On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
    Via Investor's Business Daily
    Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
    There are signs that NASDAQ:HALO may be ready to breakout. 
    Via Chartmill
    3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
    These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. 
    Via InvestorPlace
    NASDAQ:HALO is showing good growth, while it is not too expensive.
    HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing. 
    Via Chartmill
    What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
    Via Benzinga
    NASDAQ:HALO qualifies as a high growth stock and is consolidating.
    HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?. 
    Via Chartmill
    NASDAQ:HALO Shows Potential for a Breakout.
    Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective. 
    Via Chartmill
    Biotech Arvinas Stock Earns 82 RS Rating
    The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
    Via Investor's Business Daily
    Denali Therapeutics Stock Gets Technical Rating Upgrade
    Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
    Via Investor's Business Daily
    3 Biotech Stocks to Buy Now: Q3 Edition
    Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry. 
    Via InvestorPlace
    NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
    HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is probably undervalued for the fundamentals it is displaying. 
    Via Chartmill
    3 Highly Rated Biotech Stocks for Your July Buy List
    Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. 
    Via InvestorPlace
    3 Breakout Biotech Stocks on Track to Double by 2032
    The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify. 
    Via InvestorPlace
    Decoding 12 Analyst Evaluations For Halozyme Therapeutics
    Via Benzinga
    NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
    HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
    Via Chartmill
    UroGen Pharma Stock Earns 91 RS Rating
    UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
    Via Investor's Business Daily
    Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
    Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO). 
    Via Chartmill
    Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
    Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier. 
    Via Investor's Business Daily
    Arcellx Stock Earns Relative Strength Rating Upgrade
    One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
    Via Investor's Business Daily
    Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
    Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
    Via Investor's Business Daily
    Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
    In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
    Via Chartmill
    The 3 Best Healthcare Stocks to Buy in June 2024
    Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on. 
    Via InvestorPlace
    Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
    Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
    Via Investor's Business Daily
    Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
    On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
    Via Investor's Business Daily
    Krystal Biotech Stock Sees RS Rating Jump To 91
    On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
    Via Investor's Business Daily
    Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
    Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
    Via Benzinga
    Halozyme Therapeutics Scores RS Rating Jump To 91
    On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. 
    Via Investor's Business Daily
    This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.